BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

718 related articles for article (PubMed ID: 31362750)

  • 1. Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.
    Chen JP; Huang QD; Wan T; Tu H; Gu HF; Cao JY; Liu JH
    J Ovarian Res; 2019 Jul; 12(1):72. PubMed ID: 31362750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer.
    Okunade KS; Dawodu O; Adenekan M; Nwogu CM; Awofeso O; Ugwu AO; Salako O; John-Olabode S; Olowoselu OF; Anorlu RI
    Niger J Clin Pract; 2020 Aug; 23(8):1141-1147. PubMed ID: 32788493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The relationship of preoperativelymphocyte-monocyte ratio and the clinicopathological characteristics and prognosis of patients with epithelial ovarian cancer].
    Yang HM; Lou G
    Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):676-680. PubMed ID: 28926896
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum CA125 levels predict outcome of interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
    Zhang D; Jiang YX; Luo SJ; Zhou R; Jiang QX; Linghu H
    Clin Chim Acta; 2018 Sep; 484():32-35. PubMed ID: 29702068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Significance of CA125 Dynamic Change for Progression Free Survival in Patients with Epithelial Ovarian Carcinoma.
    Li Z; Yin H; Ren M; Shen Y
    Med Sci Monit; 2020 Sep; 26():e925051. PubMed ID: 32908118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
    J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative change in CA125 is an independent prognostic factor for improved clinical outcome in advanced ovarian cancer.
    Timmermans M; Zwakman N; Sonke GS; Van de Vijver KK; Duk MJ; van der Aa MA; Kruitwagen RF
    Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():364-369. PubMed ID: 31400565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the value of preoperative CYFRA21-1 in the diagnosis and prognosis of epithelial ovarian cancer in conjunction with CA125.
    Jin C; Yang M; Han X; Chu H; Zhang Y; Lu M; Wang Z; Xu X; Liu W; Wang F; Ju S
    J Ovarian Res; 2019 Nov; 12(1):114. PubMed ID: 31767040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer.
    Lee M; Chang MY; Yoo H; Lee KE; Chay DB; Cho H; Kim S; Kim YT; Kim JH
    Yonsei Med J; 2016 May; 57(3):580-7. PubMed ID: 26996555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High grade, advanced, serous ovarian cancer with low serum CA125 levels.
    Asali A; Haj-Yehia N; Zehavi T; Perry T; Beiner M; Fishman A; Kadan Y
    J Obstet Gynaecol; 2021 Oct; 41(7):1107-1111. PubMed ID: 33427544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer.
    Yang ZJ; Zhao BB; Li L
    J Ovarian Res; 2016 Sep; 9(1):57. PubMed ID: 27629537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-treatment prognostic nutritional index is superior to platelet count in predicting disease-specific survival in patients with epithelial ovarian cancer.
    Komura N; Mabuchi S; Yokoi E; Shimura K; Kawano M; Matsumoto Y; Kimura T
    Int J Gynecol Cancer; 2019 Jul; 29(6):1057-1063. PubMed ID: 31203199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes and prognostic factors of patients with epithelial ovarian cancer subjected to first-line treatment: a retrospective study of 251 cases.
    Fu Y; Wang X; Pan Z; Xie X
    Front Med; 2014 Mar; 8(1):91-5. PubMed ID: 24370920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.
    Zwakman N; van de Laar R; Van Gorp T; Zusterzeel PL; Snijders MP; Ferreira I; Massuger LF; Kruitwagen RF
    J Gynecol Oncol; 2017 Jan; 28(1):e7. PubMed ID: 27670261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative plasma D-dimer level is a useful prognostic marker in ovarian cancer.
    Yamada Y; Kawaguchi R; Iwai K; Niiro E; Morioka S; Tanase Y; Kobayashi H
    J Obstet Gynaecol; 2020 Jan; 40(1):102-106. PubMed ID: 31335252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GDF15 predict platinum response during first-line chemotherapy and can act as a complementary diagnostic serum biomarker with CA125 in epithelial ovarian cancer.
    Zhao D; Wang X; Zhang W
    BMC Cancer; 2018 Mar; 18(1):328. PubMed ID: 29580231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients.
    Feng Z; Wen H; Bi R; Duan Y; Yang W; Wu X
    BMC Cancer; 2016 Jan; 16():43. PubMed ID: 26817451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.
    van Altena AM; Kolwijck E; Spanjer MJ; Hendriks JC; Massuger LF; de Hullu JA
    Gynecol Oncol; 2010 Nov; 119(2):265-9. PubMed ID: 20797777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophil-to-Lymphocyte Ratio and Platelet Count Predict Long-Term Outcome of Stage IIIC Epithelial Ovarian Cancer.
    Zhou M; Li L; Wang X; Wang C; Wang D
    Cell Physiol Biochem; 2018; 46(1):178-186. PubMed ID: 29587273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.